Cullinan Oncology Llc Stock Today
| CGEM Stock | USD 27.12 1.82 7.19% |
Performance14 of 100
| Odds Of DistressLess than 33
|
Cullinan Oncology is selling at 27.12 as of the 30th of April 2024; that is 7.19 percent up since the beginning of the trading day. The stock's lowest day price was 25.6. Cullinan Oncology has about a 33 percent probability of financial distress in the next few years of operation but had a somewhat good performance during the last 90 days. Equity ratings for Cullinan Oncology LLC are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 31st of March 2024 and ending today, the 30th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 8th of January 2021 | Category Healthcare | Classification Health Care |
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts. The company has 43.07 M outstanding shares of which 1.68 M shares are currently shorted by private and institutional investors with about 4.41 trading days to cover. More on Cullinan Oncology LLC
Moving against Cullinan Stock
| 0.56 | EVO | Evotec SE ADR | PairCorr |
Cullinan Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Cullinan Oncology's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Cullinan Oncology or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO President | Nadim Ahmed | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering Cullinan Oncology report their recommendations after researching Cullinan Oncology's financial statements, talking to executives and customers, or listening in on Cullinan Oncology's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Cullinan Oncology LLC. The Cullinan consensus assessment is calculated by taking the average forecast from all of the analysts covering Cullinan Oncology. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the key measurements obtained from Cullinan Oncology's financial statements, Cullinan Oncology LLC is not in a good financial situation at this time. It has a very high odds of going through financial crisis in May. Financial strength of Cullinan Oncology LLC is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cullinan Oncology's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Cullinan Oncology's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Cullinan Oncology's financial leverage. It provides some insight into what part of Cullinan Oncology's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cullinan Oncology LLC (CGEM) is traded on NASDAQ Exchange in USA. It is located in One Main Street, Cambridge, MA, United States, 02142 and employs 85 people. Cullinan Oncology is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.17 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Cullinan Oncology's market, we take the total number of its shares issued and multiply it by Cullinan Oncology's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Cullinan Oncology LLC conducts business under Biotechnology sector and is part of Health Care industry. The entity has 43.07 M outstanding shares of which 1.68 M shares are currently shorted by private and institutional investors with about 4.41 trading days to cover.
Cullinan Oncology LLC currently holds about 611 M in cash with (134.28 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 13.4.
Check Cullinan Oncology Probability Of Bankruptcy
Ownership AllocationCullinan Oncology LLC retains a total of 43.07 Million outstanding shares. The majority of Cullinan Oncology LLC outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Cullinan Oncology LLC to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Cullinan Oncology. Please pay attention to any change in the institutional holdings of Cullinan Oncology LLC as this could imply that something significant has changed or is about to change at the company. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Check Cullinan Ownership Details
Cullinan Stock Price Odds Analysis
Contingent on a normal probability distribution, the odds of Cullinan Oncology jumping above the current price in 90 days from now is near 1%. The Cullinan Oncology LLC probability density function shows the probability of Cullinan Oncology stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 2.0965 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Cullinan Oncology will likely underperform. Moreover, cullinan Oncology LLC has an alpha of 1.0524, implying that it can generate a 1.05 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
Based on a normal probability distribution, the odds of Cullinan Oncology to move above the current price in 90 days from now is near 1 (This Cullinan Oncology LLC probability density function shows the probability of Cullinan Stock to fall within a particular range of prices over 90 days) .
Cullinan Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Cullinan Oncology that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Cullinan Oncology's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Cullinan Oncology's value.| Instituion | Recorded On | Shares | |
| Morgan Stanley - Brokerage Accounts | 2023-12-31 | 919.9 K | |
| Dimensional Fund Advisors, Inc. | 2023-12-31 | 915.8 K | |
| Geode Capital Management, Llc | 2023-12-31 | 655.7 K | |
| Rubric Capital Management Lp | 2023-12-31 | 626.9 K | |
| Tang Capital Management Llc | 2023-09-30 | 621.1 K | |
| State Street Corporation | 2023-12-31 | 565.4 K | |
| Deutsche Bank Ag | 2023-12-31 | 545.6 K | |
| Orbimed Advisors, Llc | 2023-12-31 | 544.8 K | |
| Parkman Healthcare Partners Llc | 2023-12-31 | 529.9 K | |
| Mpm Oncology Impact Management Lp | 2023-12-31 | 7.6 M | |
| Blue Owl Capital Holdings Lp | 2023-12-31 | 3.4 M |
Cullinan Oncology Historical Income Statement
Cullinan Oncology LLC Income Statement is one of the three primary financial statements used for reporting Cullinan's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Cullinan Oncology LLC revenue and expense. Cullinan Oncology Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Cullinan Oncology's Interest Income is very stable compared to the past year. As of the 30th of April 2024, Depreciation And Amortization is likely to grow to about 325.5 K, while Selling General Administrative is likely to drop about 40.4 K. View More FundamentalsCullinan Stock Against Markets
Picking the right benchmark for Cullinan Oncology stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Cullinan Oncology stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Cullinan Oncology is critical whether you are bullish or bearish towards Cullinan Oncology LLC at a given time. Please also check how Cullinan Oncology's historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Cullinan Oncology without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Dashboard Now
Portfolio DashboardPortfolio dashboard that provides centralized access to all your investments |
| All Next | Launch Module |
Cullinan Oncology Corporate Management
Elected by the shareholders, the Cullinan Oncology's board of directors comprises two types of representatives: Cullinan Oncology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cullinan. The board's role is to monitor Cullinan Oncology's management team and ensure that shareholders' interests are well served. Cullinan Oncology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cullinan Oncology's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jennifer Michaelson | Chief Officer | Profile | |
| Kerry Whalen | Director Devel | Profile | |
| Jeffrey Trigilio | CFO Treasurer | Profile | |
| Jacquelyn JD | Chief Officer | Profile | |
| MBA MD | Chief Officer | Profile |
How to buy Cullinan Stock?
Before investing in Cullinan Oncology, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Cullinan Oncology. To buy Cullinan Oncology stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Cullinan Oncology. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Cullinan Oncology stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Cullinan Oncology LLC stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Cullinan Oncology LLC stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Cullinan Oncology LLC, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Cullinan Stock please use our How to Invest in Cullinan Oncology guide.
Already Invested in Cullinan Oncology LLC?
The danger of trading Cullinan Oncology LLC is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Cullinan Oncology is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Cullinan Oncology. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Cullinan Oncology LLC is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Cullinan Oncology LLC is a strong investment it is important to analyze Cullinan Oncology's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cullinan Oncology's future performance. For an informed investment choice regarding Cullinan Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cullinan Oncology LLC. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income. Note that the Cullinan Oncology LLC information on this page should be used as a complementary analysis to other Cullinan Oncology's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Complementary Tools for Cullinan Stock analysis
When running Cullinan Oncology's price analysis, check to measure Cullinan Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cullinan Oncology is operating at the current time. Most of Cullinan Oncology's value examination focuses on studying past and present price action to predict the probability of Cullinan Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cullinan Oncology's price. Additionally, you may evaluate how the addition of Cullinan Oncology to your portfolios can decrease your overall portfolio volatility.
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |
Is Cullinan Oncology's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cullinan Oncology. If investors know Cullinan will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cullinan Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.69) | Return On Assets (0.23) | Return On Equity (0.31) |
The market value of Cullinan Oncology LLC is measured differently than its book value, which is the value of Cullinan that is recorded on the company's balance sheet. Investors also form their own opinion of Cullinan Oncology's value that differs from its market value or its book value, called intrinsic value, which is Cullinan Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cullinan Oncology's market value can be influenced by many factors that don't directly affect Cullinan Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cullinan Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cullinan Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cullinan Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.